• Home
  • About these Guidelines
  • Acknowledgments
  • Contents
  • Feedback

PEP Guidelines

  • Assessment of the risk
    • Assessment of the risk of HIV transmission
    • What is the HIV transmission risk/exposure?
    • What is the HIV status of the source individual?
    • What is the HIV status of the exposed individual?
  • Immediate management and follow-up
    • Immediate management
    • Clinical assessment and follow up
    • Laboratory assessment and follow-up
  • Prescribing PEP
    • When to Prescribe PEP
    • PEP recommendations after occupational exposure
    • Prescribing PEP
    • Recommended PEP Regimens
    • Medications and Cautions
  • Exposure to other conditions
    • Hepatitis B
    • Sexually transmissible infections
    • Hepatitis C
    • Pregnancy and breastfeeding
    • Tetanus
  • Additional clinical management issues
    • Preventive behaviours while being managed for HIV exposure
    • Individuals at risk of HIV acquisition who decline PEP
    • Individuals at negligible risk of HIV transmission who request PEP
    • Individuals who re-present for NPEP
    • Individuals who are on PrEP
    • Transitioning from PEP to PrEP
    • Renal disease
    • Gender identity and history
    • Individuals who have been sexually assualted
    • Children
    • Prisoners and detainees
    • Individuals who commenced PEP overseas
    • Risk communication: understanding the risk of exposure
  • Further information
    • References
    • Information for clinicians
    • Information for patients
    • Appendix 1: Drugs commonly prescribed in PEP regimens
Post-Exposure Prophylaxis after Non-Occupational Exposure to HIV
  • Home
  • Additional clinical management issues
Preventive behaviours while being managed for HIV exposure
Individuals at risk of HIV acquisition who decline PEP
Individuals who re-present for NPEP
Individuals at negligible risk of HIV transmission who request PEP
Individuals who are on PrEP
Transitioning from PEP to PrEP
Renal disease
Gender identity and history
Individuals who have been sexually assaulted
Children
Prisoners and detainees
Individuals who commenced PEP overseas
Risk communication: understanding the risk of exposure

Endorsed by

Australsian Society for Infectious Diseases

Funded By: The Australian Government Department of Health
Disclaimer: Whilst the Australian Department of Health provides financial assistance to ASHM, the material contained in this resource produced by ASHM should not be taken to represent the views of the Australian Department of Health. The content of this resource is the sole responsibility of ASHM.

  • Assessment of the risk
    • Assessment of the risk of HIV transmission
    • What is the HIV transmission risk/exposure?
    • What is the HIV status of the source individual?
    • What is the HIV status of the exposed individual?
  • Immediate management and follow-up
    • Immediate management
    • Clinical assessment and follow up
    • Laboratory assessment and follow-up
  • Prescribing PEP
    • When to Prescribe PEP
    • PEP recommendations after occupational exposure
    • Prescribing PEP
    • Recommended PEP Regimens
    • Medications and Cautions
  • Exposure to other conditions
    • Hepatitis B
    • Sexually transmissible infections
    • Hepatitis C
    • Pregnancy and breastfeeding
    • Tetanus
  • Additional clinical management issues
    • Preventive behaviours while being managed for HIV exposure
    • Individuals at risk of HIV acquisition who decline PEP
    • Individuals at negligible risk of HIV transmission who request PEP
    • Individuals who re-present for NPEP
    • Individuals who are on PrEP
    • Transitioning from PEP to PrEP
    • Renal disease
    • Gender identity and history
    • Individuals who have been sexually assualted
    • Children
    • Prisoners and detainees
    • Individuals who commenced PEP overseas
    • Risk communication: understanding the risk of exposure
  • Further information
    • References
    • Information for clinicians
    • Information for patients
    • Appendix 1: Drugs commonly prescribed in PEP regimens